Adjutec Participates at BioEurope and NOME Meetings

Oslo, Norway, 2 November 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. The Company will attend the BioEurope meeting in Munich 6-7th November and the Nordic Mentoring (NOME) Annual meeting in Copenhagen 9^th November.

BioEurope is the largest partnering meeting in Europe and an important platform for connecting with partners and investors. Adjutec is preparing for the next year phase 1 program activities. All relevant partners are on-board and the BioEurope meeting secures investor support for this and next year capital raise, to execute the early-stage clinical program.

The NOME Annual meeting in Copenhagen is a networking platform for entrepreneurs and investors supported by Novo Nordisk. Adjutec is an alumni of their mentoring program that included access to mentors and a business development bootcamp in the US. This is a great opportunity to connect with Nordic investors and learn about emerging new technologies.

About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

AMR is a global health threat with an estimated 5mill associated deaths, including 1.27mill deaths attributable to bacterial AMR in 2019. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.

About AdjuTec Pharma

AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.

For more information, please visit www.adjutecpharma.com

Please contact: info@adjutecpharma.com

Follow us on LinkedIn and Twitter